Skip to main content

bevacizumab (Avastin®)

 

Status: In progress

In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Medicine details

Medicine name bevacizumab (Avastin®)
Formulation 25 mg/ml concentrate for solution for infusion
Reference number 5044
Indication

As above

Company Roche Products Ltd
BNF chapter Malignant disease & immunosuppression
Submission type Resubmission
Status In progress
NMG meeting date 11/05/2022
AWMSG meeting date 15/06/2022
Date of issue TBC
Follow AWTTC: